CTNM · Contineum Therapeutics, Inc.
$17.19
+1.17 (+7.30%)
At close · Aug 21
Market Cap
$646.71M
Shares
37.62M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$17.19
Open$16.18
Day$15.88–17.35
52W close$9.17–17.19
Avg vol 30d413K
Short int2.8M · 7.5% float · 13.5d
Short vol63%
Last earningsOct 30, 2025
DataApr 2024–Aug 2026
Filing10-Q · Jul 30
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 30, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+30%
above
Price vs 50-day avg
+19%
above
RSI (14)
66
neutral
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+22%
trailing
6-month return
+12%
trailing
YTD return
+50%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.50% of float · ▲ +15.5% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 2-yr high, broad support
Squeeze score
100
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+0%
Y/Y
Free cash flow
$-55.5M
Balance sheet
$75.6M
net cash
Quant / Vol
risk profile
Volatility
68%
annualized · 1-yr
Max drawdown
−30%
past year
ATR
6.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+30%
Bullish
Price vs 50-day avg
+19%
Bullish
RSI (14)
66
Neutral
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $13 — 50d above 200d
Institutional flow
Accumulating
+12% holders QoQ · +28 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
7.50% of float · ▲ +15.5% MoM · 13.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
101 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $9
Now $17 · 100%
Range high $17
vs 200-day avg +30%
vs 50-day avg +19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTNM
this stock
Contineum Therapeutics, Inc.
|
$646.71M | +50.4% | -100.0% | — | 7.5% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTNM | +21.1% | +22.3% | +12.1% | +11.0% | +50.4% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +22.5% | +18.6% | +0.5% | +8.5% | +38.1% |
Key facts
CIK
1855175
CUSIP
21217B100
13F (30d)
98 filings
96 filers
Visit website
Investor relations